The Next Step in Europe
Join us for the first-ever Cannabis Europa in Spain, to discuss the most pertinent questions for Spanish and European industries.
Spain represents Europe’s largest cannabis market yet to legalise medical cannabis. However, with strong social support fueling a shift in the political debate and changes abound across the continent, reform is inevitable. With 84% of the population in favour of medical cannabis, a burgeoning commercial industry and one of the most innovative biomedical sectors in the world, Spain is fast becoming the most promising industry in the region.
Learn, Network, Debate
Cannabis Europa Madrid will bring together 250+ senior decision-makers to address the issues of regulating cannabis in Spain and around Europe.
- Attend a balance of political, scientific and business discussions led by esteemed moderators and carefully curated panels
- Network with country delegations comprising thought-leading politicians, regulators, patient advocates, medical practitioners and researchers in order to shape the future of medical cannabis in Europe
- Discover the latest European investment opportunities and trends in the world’s fastest-growing cannabis market.
Reserve your seat today to avoid disappointment.
*Early Bird Tickets available until 8th January 2020. These tickets are limited and subject to availability.
Join us to discover the latest news from the European cannabis sector, learn from our world-renowned speakers and network with industry-leading professionals.
Cannabis Europa Madrid will be taking place at the Intercontinental Hotel, in the heart of Madrid.
Paseo de la Castellana, 49, 28046 Madrid, Spain
The venue is a 20 minute drive from Madrid-Barajas Adolfo Suárez Airport and a 40 minute journey via public transport.
Dr. Axel Gille is Managing Director of Aurora Europe GmbH and Aurora Deutschland GmbH. He joined the company 2018 and is responsible for the strategic direction with the goal of establishing Aurora as the clear market leader in all European countries where medical cannabis is licensed. A chemist by education, he spent more than 20 years in management consulting at the global advisory firms McKinsey and KMPG. There he advanced ambitious strategic and overarching operational goals and gained extensive international management experience.
Carola Pérez has a degree in Audiovisual Communication, a field to which she has dedicated most of her professional life. She currently chairs the Spanish Medicinal Cannabis Observatory and is the founder of the association of therapeutic users dosemociones, where she advises, supports all those patients who use cannabis for medicinal purposes and works for the regulation of therapeutic cannabis.
Piernicola Pedicini is an Italian politician and member of the European Parliament since 2014. He is a member of the Committee on Committee on Economic and Monetary Affairs, and a substitute member of the Committee on the Environment, Public Health and Food Safety. He was one of the co-sponsors of the Resolution on the use of cannabis for medicinal purposes voted in the European Parliament in February 2019.
Cristina Romero de Alba is a Partner at LOYRA Abogados y Asesores since April 2011. She leads the international practice area of Loyra. Cristina regularly advises operators and investors in licensing, M&A and general regulatory and compliance procedures in regulated industries including cannabis for medicinal, cosmetics and food use.
José Antonio de la Puente has been the CEO of Alcaliber S.A.U. since 2004. Alcaliber is a leading independent supplier of active pharmaceutical ingredients for the international pharmaceutical industry. He is also the CEO of Linneo Health since October 2018, a Spanish Company founded for the activities of cultivation, production, manufacturing, import, export, distribution and trade of cannabis and cannabis products for medical and scientific purposes, as well as research linked to the development of these activities.
Viola Brugnatelli is the scientific director of Cannabiscienza, an e-learning academy for Italian health care professionals on Medical Cannabis and the Endocannabinoid System. Dr Brugnatelli is a lecturer on Medical Cannabis at the University of Padua (Italy) as well as a researcher at the Department of Neuroscience within the same institute. Since 2012 she is an active member of IACM and ICRS, and was recently nominated IACM Italian Ambassador. Dr Brugnatelli advocates for patient-inspired clinical research and collaborates with non-for-profit organisations. In 2018 Brugnatelli co-founded a non-for-profit which lobbies for women equality in the European cannabis sphere.
Stephen is Co-Founder and Managing Director of Prohibition Partners, the leading source of intelligence and insights into the European cannabis industry and Co-Founder of Cannabis Europa, Europe’s premier medical cannabis conference. Stephen is also Co-Founder & Director of NOBL, a global leader in cannabis data, events and media, managing a portfolio of some of the best-known brands in the industry. With a background in technology, digital media and corporate finance, Stephen works with investors, entrepreneurs and regulators to identify, qualify and maximise the opportunities in this emerging frontier.
Bruno Maia is a Portuguese MD, specialist in Neurology and Critical Care Medicine. He works in the acute care of stroke patients and is responsible for the Neurovascular Ultrasonographic Laboratory at Centro Hospitalar de Lisboa Central (terciary hospital located in Lisbon).
Headquartered in Berlin, Germany, Aurora Europe (www.auroramedicine.com) is one of the largest authorised importers and distributors of medical cannabis in the European Union. Aurora Europe is a subsidiary of the publicly listed cannabis producer, Aurora Cannabis Inc., which is headquartered in Edmonton, Alberta, Canada, with and sales and operations across five continents and 25 countries, 19 of which are in Europe, including Aurora Medicine España.
Aurora supplies high-quality medical cannabis products to patients throughout Europe and has been leading the German market since 2015. Aurora’s cannabis production and distribution facilities are certified under EU Good Manufacturing Practices (GMP), with a funded capacity of more than 625,000 kg of cannabis per year, making Aurora one of the world's largest and leading cannabis companies.
Synoptis Industrial is a European Good Manufacturing Practice (EU GMP) certified pharmaceutical importer, packing, and Qualified Person (QP) certification site. The company provides full end-to-end supply chain services, delivering pharmaceutical products from manufacturers to clients across Europe. Synoptis’ operations activity deals with the import and export of both regular and controlled pharmaceutical products, including cannabis products, and is covered by all relevant controlled drugs licenses where necessary. Synoptis Industrial is a part of the NEUCA Group, a leader in the pharmaceutical logistics and wholesale market in Poland.
Epperly | Elam, LLP guides its cannabis operator and investor clients through venture-financing deals, corporate governance, regulatory compliance, and trans-border mergers and acquisitions. Most recently, the firm served as legal counsel on Terrascend's acquisition of the Apothecarium ($118M) and ABI (~$12M), as well serving as corporate counsel for Ebbu in its acquisition by Canopy ($429M).
Khiron Life Sciences is a fully vertically integrated medical cannabis company based in Colombia. In addition to its medical business, Khiron has developed the Kuida brand of CBD skin care products sold in Latam, USA & Europe. Khiron is publicly traded on the NY, Toronto & Frankfurt Stock Exchanges.